Karjula, T., Kemi, N., Niskakangas, A., Mustonen, O., Puro, I., Pohjanen, V.-M., Kuopio, T., Elomaa, H., Ahtiainen, M., Mecklin, J.-P., Seppälä, T. T., Wirta, E.-V., Sihvo, E., Väyrynen, J. P., Yannopoulos, F., & Helminen, O. (2023). The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma. In European Journal of Surgical Oncology (Vol. 49, Issue 7, pp. 1298–1306). Elsevier BV. https://doi.org/10.1016/j.ejso.2023.02.009
The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma
|Author:||Karjula, Topias1; Kemi, Niko1; Niskakangas, Anne1;|
1Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Biological and Environmental Science, University of Jyväskylä, 40014, Jyväskylä, Finland
3Department of Pathology, Central Finland Health Care District, 40620, Jyväskylä, Finland
4Department of Education and Research, Central Finland Health Care District, 40620, Jyväskylä, Finland
5Faculty of Sport and Health Sciences, University of Jyväskylä, 40014, Jyväskylä, Finland
6Faculty of Medicine and Health Technology, Tampere University and TAYS Cancer Center, Tampere University Hospital, 33520, Tampere, Finland
7Department of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, 00290, Helsinki, Finland
8Applied Tumor Genomics, Research Program Unit, University of Helsinki, 00290, Helsinki, Finland
9Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, 33520, Tampere, Finland
10Central Hospital of Central Finland, 40014, Jyväskylä, Finland
11University Hospital and University of Oulu, 90014, Oulu, Finland
12Department of Cardiothoracic Surgery, Oulu University Hospital, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 1.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe20230925136840
|Publish Date:|| 2023-09-25
Objective: To evaluate the prognostic value of tumor budding and tumor-stroma ratio (TSR) in resected pulmonary metastases of colorectal carcinoma (CRC).
Methods: In total, 106 pulmonary metastasectomies were performed to 74 patients in two study hospitals during 2000–2020. All relevant clinical data were retrospectively collected. Tumor budding based on the International Tumor Budding Consensus Conference recommendations and TSR in the first resected pulmonary metastases and primary tumors were evaluated from diagnostic hematoxylin-eosin-stained histopathological slides.
Results: 60 patients (85.7%) had low tumor budding (≤5 buds/field) and 10 patients (14.3%) had high tumor budding (>5 buds/field) in their first pulmonary metastases of CRC. 5-year overall survival rates of pulmonary metastasectomy in low and high total tumor budding were 28.3% and 37.3% (p = 0.387), respectively. 19 patients (27.1%) had low TSR and 51 patients (72.9%) had high TSR. The 5-year overall survival rates were 32.9% in low and 28.6% in high TSR of first pulmonary metastases (p = 0.746). Tumor budding and TSR did not provide prognostic value in Cox multivariate analysis. Tumor budding and TSR in resected pulmonary metastases were not associated with those of the primary tumor.
Conclusion: Tumor budding and TSR in the resected pulmonary metastases of CRC showed no statistically significant prognostic value, however, additional well-powered confirmatory studies are needed.
European journal of surgical oncology
|Pages:||1298 - 1306|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was funded by Instrumentarium Science Foundation (O.H), Mary and Georg C. Ehrnrooth Foundation (O.H) and Finnish State Research Funding (O.H, J-P.M), Cancer Foundation Finland (J.P.V), J&A Erkko Foundation (J-P.M). The funding sources had no involvement in the study design, collection of data, analysis and interpretation of the data, in writing the report or submitting decision of the article.
© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).